| Patient | Frederick Law Olmsted |
|---|---|
| Date of birth | 1953-04-26 |
| Identifiers | MRN HR-NI022-SYN; SSN (made up) 000-22-5519 |
| Document date | 2026-08-04 |
| Author | Nathan Calder, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-month dementia review. [S]
Mr. Olmsted returns with his caregiver three months after his first visit, nine weeks after starting donepezil 5 mg each morning. He has had no nausea, diarrhea, loss of appetite, dizziness, fainting, or vivid dreams. His caregiver feels he is a little more engaged in the mornings, and his memory is otherwise unchanged. The night-time confusion during his cold three weeks ago stopped as soon as the diphenhydramine cold medicine was stopped, and his cough has gone. He stopped driving after the consultation and walks with company most days. He wears a medical identification bracelet. His caregiver completed the Zarit Burden Interview today and describes broken sleep, worry about leaving him alone, and little time off. [S]
| Element | Detail |
|---|---|
| Medicine | Donepezil 5 mg for nine weeks; no side effects |
| Course | Memory unchanged; slightly more engaged in the mornings |
| Interval illness | Cold with night-time confusion from diphenhydramine three weeks ago, resolved |
| Safety | No driving; medical identification bracelet; no wandering |
| Caregiver | Zarit Burden Interview 24; broken sleep and little time off |
| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Negative | No nausea, diarrhea, or loss of appetite |
| Cardiovascular | Negative | No fainting or lightheadedness |
| Neurological | Positive | Memory loss unchanged; no night-time confusion since the antihistamine was stopped |
| Psychiatric | Negative | Mood steadier; no hallucinations or agitation |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Donepezil 5 mg oral tablet, one tablet by mouth each morning | One tablet by mouth each morning with breakfast | Oral route | 2026-06-02 to 2026-08-04 | completed | S |
| Donepezil 10 mg oral tablet, one tablet by mouth each morning | One tablet by mouth each morning with breakfast | Oral route | 2026-08-04 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-08-04 | Body height | 175 | cm | S |
| 2026-08-04 | Body weight | 71.2 | kg | S |
| 2026-08-04 | Body mass index (BMI) [Ratio] | 23.2 | kg/m2 | S |
| 2026-08-04 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-08-04 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-08-04 | Heart rate | 62 | /min | S |
| 2026-08-04 | Respiratory rate | 14 | /min | S |
| 2026-08-04 | Body temperature | 36.6 | Cel | S |
| 2026-08-04 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
Vital signs recorded on 2026-08-04; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Alert, pleasant, and engaged |
| Cardiovascular | Regular rhythm at 62 per minute; blood pressure 128/76 mmHg; weight 71.2 kg |
| Neurological | Oriented to person and place, not to date; no new focal signs; normal gait |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Mild dementia (major neurocognitive disorder), progressive, amnestic-predominant with executive difficulty, type undetermined; CDR global 1 | active | confirmed | F03.A0 | S — Synthetic modern coding of his documented failing memory; the cause is unknown, so the type is left unspecified. Stage and scores are synthetic. |
| Common cold, with two nights of increased confusion after an over-the-counter nighttime cold medicine containing diphenhydramine; resolved | resolved | confirmed | J00 | S — Synthetic intercurrent illness at an unscheduled visit; it does not echo a documented illness. |
| Progressive memory loss over about two years with decline in managing his work and affairs, under evaluation for dementia or mild cognitive impairment | resolved | confirmed | R41.3 | S — Synthetic presenting concern at the index visit, superseded by the dementia diagnosis at the four-week visit; the failing memory is documented (D). |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Medication review with the AGS Beers Criteria (anticholinergic burden, sedatives, sleeping pills, antipsychotics) | Every visit | Completed today | Diphenhydramine cold medicine stopped after the sick visit; no anticholinergic or sedating drugs now |
| Survey | Neuropsychiatric symptom screen (NPI-Q) | Every visit | Completed today | Mild apathy, less in the mornings; no hallucinations, agitation, or wandering; the night-time confusion has not recurred |
| Medication safety | Cholinesterase inhibitor tolerability and benefit: heart rate, fainting, nausea, diarrhea, weight, sleep and dreams | Each follow-up on treatment | Completed today | On 5 mg for nine weeks: heart rate 62, no fainting, no gastrointestinal effects, weight 71.2 kg (down 0.6 kg), no vivid dreams; increasing to 10 mg |
| Medication safety | Antipsychotic appropriateness and taper review | Every visit if on an antipsychotic | Not indicated | Not on an antipsychotic |
| Examination | Vascular risk-factor control (blood pressure, lipids, glucose, smoking) | Every visit | Completed today | Blood pressure 128/76 mmHg; lipids at the wellness visit |
| Examination | Home safety evaluation | At diagnosis and each follow-up | Deferred | The home safety checklist given at diagnosis was not reviewed at this visit, a deviation from the each-follow-up item. There have been no falls, burns, or wandering, so no harm is evident. Corrective action: the checklist is reviewed at the six-month visit |
| Survey | Cognitive test (MoCA) | Annually; every visit if a change is reported | Up to date | MoCA 19 three months ago; no change reported |
| Survey | ADL (Katz) and IADL (Lawton-Brody) | Annually, and at any reported change | Up to date | No change reported since the first visit |
| Survey | Dementia stage (CDR or FAST) | Annually | Up to date | CDR 1 two months ago |
| Survey | Depression screen (PHQ-9) | Annually, and at any reported change | Up to date | PHQ-9 6 three months ago; mood steadier today |
| Examination | Fall-risk assessment (Timed Up and Go, gait and balance) | Annually | Up to date | No falls; Timed Up and Go 11 seconds three months ago |
| Examination | Driving safety (CDR-based) | At diagnosis and annually | Completed today | No driving since the consultation |
| Self-management | Firearms, wandering, and financial safety | At diagnosis and with any change | Completed today | No firearms; medical identification bracelet worn; no wandering; caregiver oversees finances |
| Survey | Caregiver burden (Zarit Burden Interview) and caregiver needs | At diagnosis, then every 6 to 12 months | Completed today | Zarit Burden Interview 24, moderate burden (21 or more): education, adult day program, and respite information given; the item missed at diagnosis is now done |
| Self-management | Advance care planning and goals of care | At diagnosis, then annually and at stage changes | Completed today | Health care agent named and his values and wishes recorded today, with him taking full part |
| Laboratory | TSH, vitamin B12, blood count, and metabolic panel | At diagnosis; repeat only with acute cognitive worsening | Up to date | Normal at diagnosis; no acute change to repeat them |
| Laboratory | Syphilis and HIV testing | Only with risk factors or atypical features | Not indicated | No risk factors |
| Imaging | Structural brain MRI, non-contrast | Once at diagnosis; repeat only with an atypical course or focal change | Up to date | Done once at diagnosis; no atypical course |
| Laboratory | Amyloid or tau biomarkers (blood, CSF, or amyloid PET) and APOE genotype | Before anti-amyloid therapy, or when the result would change care | Not indicated | Declined two months ago; no change in his wishes |
| Imaging | Anti-amyloid antibody therapy with ARIA surveillance MRI | Only if anti-amyloid therapy is started | Not indicated | Not chosen |
| Self-management | Lifestyle: aerobic exercise about twice a week, hearing, vision, sleep, social engagement | Ongoing | Completed today | Walks most days with company; adult day program will add social contact |
| Referral | Dementia care navigation and caregiver support program | At enrollment, with ongoing support | Completed today | Caregiver education program and adult day program arranged |
| Self-management | Vaccination status (influenza, pneumococcal, zoster, COVID-19, Tdap) | Yearly, per the CDC schedule | Due | At the wellness visit in about six weeks |
Goal progress:
Guideline basis: Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology (2001); Practice parameter update: evaluation and management of driving risk in dementia: report of the Quality Standards Subcommittee of the American Academy of Neurology (2010); Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care (2025); American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023); CMID: Clinical Monitoring Intelligence Database, Non-Alzheimer's dementia and Alzheimer's disease monographs (2026)
Follow-up: Annual wellness visit in about six weeks. Six-month dementia review in about three months. Next scheduled visit 2026-09-15: subsequent annual wellness visit. [S]